Videos

The series concludes with guidance on adopting emerging therapies, managing patient expectations, and addressing unmet needs in dry eye care.

Explore the complexities of LASIK candidacy, lens options, and managing patient expectations for optimal post-operative satisfaction.

Explore the complexities of vision correction for artists, including monovision options and the benefits of light adjustable lenses in surgery.

Panelists discuss how faricimab and aflibercept 8 mg compare in drying and durability and how clinicians manage IOP considerations tied to injection frequency, volume, and syringe variability.

Explore the complexities of vision correction for artists, including monovision options and the benefits of light adjustable lenses in surgery.

Panelists discuss how real-world adherence to loading doses and thoughtful switching or reloading strategies can optimize durability and outcomes, particularly in undertreated patients.

Explore advanced IOL selection in cataract surgery, emphasizing patient-centered choices and successful outcomes with the enVista Envy lens.

Strategies for tapering and sustaining therapy once stabilization is achieved are discussed.

The importance of combining clinical metrics and patient-reported outcomes is examined.

Panelists discuss how higher-dose and dual-pathway anti-VEGF agents enable longer intervals, improved fluid control, and more flexible treatment strategies across retinal vascular diseases.

They evaluate key efficacy data and patient outcomes from the COMET-2 and COMET-3 clinical trials.

The team reviews acoltremon’s mechanism in promoting basal tear production and maintaining ocular surface health.

Panelists discuss how faricimab’s dual VEGF-A and Ang-2 inhibition may offer vascular stability advantages over single-pathway blockade, despite ongoing questions about Ang-2’s independent therapeutic impact.

Panelists discuss how aflibercept’s structural design and the higher molar dose of its 8-mg formulation enhance VEGF binding, treatment durability, and clinical predictability.

Panelists discuss new DED treatments like Miebo and Vevye and how they integrate into treatment algorithms.

Experts highlight management nuances in patients with neuropathic pain, post–refractive surgery complications, or contact lens intolerance.

The panel addresses common patient frustrations and therapeutic limitations in today’s dry eye landscape.

Panelists share how they tailor therapy based on patient characteristics, symptoms, and clinical findings.

Panelists discuss how key biologic and clinical distinctions—such as ischemia, leakage patterns, and modality-specific insights—guide tailored treatment strategies for BRVO, CRVO, and DME.

Panelists discuss how differing disease mechanisms, inflammatory drivers, and clinical priorities across AMD, DME, and RVO shape individualized therapeutic goals and the use of newer anti-VEGF agents.

The discussion explores how basal and reflex tears differ and why composition impacts sustained eye comfort.

Experts explain how differentiating these subtypes guides treatment choices and outcomes.

A new treatment is presented that eliminates the root cause of the disease and restores ocular surface health.

Hipsley shares insights into ocular biomechanics and dynamic range of focus, that can help the field to work toward vision restoration and increase eye health.

Discover how RGB technology enhances eye disease diagnosis, improving accuracy and efficiency in clinical practice with advanced imaging techniques.

Advanced imaging technologies like intraoperative OCT and heads-up displays enhance surgical precision and patient outcomes in retina surgery.

A study reveals that cryopreserved amniotic membrane enhances recovery and reduces infection risk in post-corneal cross-linking patients.

Donaldson introduces the panel and outlines the series’ focus on improving dry eye management through tear function optimization.